Oryzon Genomics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference and at the 17th Annual Biotech in Europe Forum

BARCELONA, SPAIN and CAMBRIDGE MA.

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that Dr. Carlos Buesa, Oryzon’s Chief Executive Officer, will present a corporate overview at the 19th Annual Rodman and Renshaw Global investment Conference. The conference will take place on September 11-12, 2017, at the Lotte New York Palace Hotel in New York City. Dr. Buesa is scheduled to present on Monday, September 11th at the Louis Room at 10:25 am ET.

Dr. Buesa will also present a corporate overview at the 17th Annual Biotech in Europe Forum for Global Partnering and Investment. This event will take place on September 26-27 in Basel Switzerland, at the The Congress Center Basel. Dr. Buesa is scheduled to present on September 26th in the morning CNS track starting at 11.30 am CET. Dr. Buesa will also participate in a Panel Discussion entitled Neuroscience I – BD&L that will be co-chaired by Dr. Tim Lucker, Senior Director, Emerging Technology & Innovation from Eli Lilly, and Dr. Charles Bailey, Head of Business Development & Licensing in Neuroscience at Novartis.

Click here to see the full Press Release